TheraXyte Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $10M

  • Investors
  • 1

TheraXyte General Information

Description

Developer of extracellular vesicle (EV)-mediated drug delivery and EV-based novel therapeutics. The company has developed an EV-based drug delivery platform, enabling to address upcoming challenges for various therapeutic applications, to advance EV research from the laboratory to the bedside, and to positively impact human health by overcoming unsolved problems.

Contact Information

Website
theraxyte.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • F601, Building 3, No. 9, Life Science Park Road
  • Changping District
  • Beijing, 102206
  • China
+86 010
Primary Industry
Drug Delivery
Vertical(s)
LOHAS & Wellness, Life Sciences
Corporate Office
  • F601, Building 3, No. 9, Life Science Park Road
  • Changping District
  • Beijing, 102206
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TheraXyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 11-Jul-2022 $10M Completed Generating Revenue
To view TheraXyte’s complete valuation and funding history, request access »

TheraXyte Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

TheraXyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024002311-A1 Methods for manufacturing and using extracellular vesicles Inactive 29-Jun-2022
WO-2023178500-A1 Therapeutic vesicles and methods of processing the same Inactive 22-Mar-2022
WO-2023179647-A1 Therapeutic vesicles and methods of processing the same Inactive 22-Mar-2022
US-20250066727-A1 Compositions and methods for culturing stem cells Pending 31-Dec-2021
WO-2023123299-A1 Compositions and methods for culturing stem cells Inactive 31-Dec-2021 C12N5/063
To view TheraXyte’s complete patent history, request access »

TheraXyte Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
NHH Ventures Corporate Venture Capital Minority
To view TheraXyte’s complete investors history, request access »

Ready to get started?

Request a free trial

TheraXyte FAQs

  • When was TheraXyte founded?

    TheraXyte was founded in 2019.

  • Where is TheraXyte headquartered?

    TheraXyte is headquartered in Beijing, China.

  • What industry is TheraXyte in?

    TheraXyte’s primary industry is Drug Delivery.

  • Is TheraXyte a private or public company?

    TheraXyte is a Private company.

  • What is TheraXyte’s current revenue?

    The current revenue for TheraXyte is .

  • How much funding has TheraXyte raised over time?

    TheraXyte has raised $10M.

  • Who are TheraXyte’s investors?

    NHH Ventures has invested in TheraXyte.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process